RE: nomlungo5 Feb 2019 16:58
Artificial heart valves... thousands of successful implants so far and the cornea turnover from the German jv tie-up is offsetting the 'costs of the facility as we continue with the development and commercialisation plans for the CardioPure products'. As the RNS states:
Joint Venture GBM-v delivered sales of £1.8m (2017: £1.1m), an increase of 64% on a constant currency basis, as demand increased for corneal products. This contribution largely offsets the operational costs of the facility as we continue with the development and commercialisation plans for the CardioPure products.